This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): Alteplase, Actilyse, Activacin, t-PA, RG3626, GRTPA
Description: Recombinant tissue plasminogen activator (tPA) is a drug that dissolves the blood clot-impairing blood flow that causes heart attacks, strokes, and other thrombotic events. It catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Genentech licensed Activase rights in Japan to Kyowa Hakko Kogyo, and in Europe to Boehringer Ingelheim.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Boehringer Ingelheim GmbH Kyowa Hakko Kirin Co., Ltd.
Pink Sheet In Brief: Genentech's Activase
Additional information available to subscribers only: